Published in J Cancer on December 07, 2010
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Assessing prostate cancer growth with citrate measured by intact tissue proton magnetic resonance spectroscopy. Prostate Cancer Prostatic Dis (2012) 1.42
Evaluation of protein biomarkers of prostate cancer aggressiveness. BMC Cancer (2014) 0.86
African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian men. Urol Oncol (2014) 0.84
Pre- and post-operative nomograms to predict recurrence-free probability in korean men with clinically localized prostate cancer. PLoS One (2014) 0.79
Elevated hyaluronan and hyaluronan-mediated motility receptor are associated with biochemical failure in patients with intermediate-grade prostate tumors. Cancer (2014) 0.78
Prognostic value of transformer 2β expression in prostate cancer. Int J Clin Exp Pathol (2015) 0.77
The impact of body mass index on treatment outcomes for patients with low-intermediate risk prostate cancer. BMC Cancer (2016) 0.77
African-american race is a predictor of seminal vesicle invasion after radical prostatectomy. Clin Genitourin Cancer (2014) 0.75
Prognostic value of inhibitors of apoptosis proteins (IAPs) and caspases in prostate cancer: caspase-3 forms and XIAP predict biochemical progression after radical prostatectomy. BMC Cancer (2015) 0.75
Myosin isoform expressed in metastatic prostate cancer stimulates cell invasion. Sci Rep (2017) 0.75
Cancer statistics, 2009. CA Cancer J Clin (2009) 83.57
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA (1998) 21.31
Natural history of progression after PSA elevation following radical prostatectomy. JAMA (1999) 14.35
Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol (2010) 8.93
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med (2004) 7.98
A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med (1989) 7.01
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet (2005) 6.99
Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol (2009) 5.62
Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am (2001) 5.39
Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2005) 4.89
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol (1999) 4.78
Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol (2003) 4.66
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol (1993) 4.55
Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol (2004) 4.41
Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol (2003) 4.28
Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol (2002) 3.61
Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol (2009) 3.24
Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. J Clin Oncol (2007) 2.97
Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology (2000) 2.35
Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol (2001) 2.31
Prediction of progression following radical prostatectomy. A multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol (1996) 1.98
Is tumor volume an independent prognostic factor in clinically localized prostate cancer? J Urol (2004) 1.87
Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol (1997) 1.86
Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol (2008) 1.86
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol (2001) 1.72
Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J Clin Oncol (2008) 1.69
Prognostic factors in prostate cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med (2000) 1.67
Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology (2005) 1.63
Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. Urology (2003) 1.62
Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. Urology (2002) 1.56
Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology (1996) 1.55
The significance of a positive bladder neck margin after radical prostatectomy: the American Joint Committee on Cancer Pathological Stage T4 designation is not warranted. J Urol (2010) 1.47
Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol (2007) 1.46
Positive surgical margins with radical retropubic prostatectomy: anatomic site-specific pathologic analysis and impact on prognosis. Urology (1999) 1.44
Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol (1998) 1.42
Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol (1993) 1.33
Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol (2010) 1.33
Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer (2009) 1.29
Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer (1997) 1.29
The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol (1994) 1.29
Radical prostatectomy for pathological Gleason 8 or greater prostate cancer: influence of concomitant pathological variables. J Urol (2002) 1.29
Survival in blacks and whites after treatment for localized prostate cancer. J Urol (1996) 1.26
Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer. Hum Pathol (1998) 1.26
Prostate cancer is highly predictable: a prognostic equation based on all morphological variables in radical prostatectomy specimens. J Urol (2000) 1.25
Positive surgical margins after radical prostatectomy: do they have an impact on biochemical or clinical progression? BJU Int (2008) 1.25
Do younger men have better biochemical outcomes after radical prostatectomy? Urology (2004) 1.24
Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. J Urol (2000) 1.23
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology (2003) 1.23
Outcome of patients with Gleason score 8 or higher prostate cancer following radical prostatectomy alone. J Urol (2002) 1.22
Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol (2003) 1.20
Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol (2004) 1.20
Prognostic factors for survival of patients with pathological Gleason score 7 prostate cancer: differences in outcome between primary Gleason grades 3 and 4. J Urol (2001) 1.20
The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol (1995) 1.19
Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins. J Urol (2006) 1.18
Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol (1994) 1.18
Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials. Eur J Cancer (2006) 1.18
Disease recurrence in black and white men undergoing radical prostatectomy for clinical stage T1-T2 prostate cancer. J Urol (2000) 1.16
CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. J Urol (1998) 1.16
Predicting disease recurrence in intermediate and high-risk patients undergoing radical prostatectomy using percent positive biopsies: results from CaPSURE. Urology (2002) 1.16
Pathologic assessment of the surgical specimen. Urol Clin North Am (2001) 1.12
Gleason score 7 prostate cancer: a heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology (2000) 1.11
Microvessel density in prostate cancer: lack of correlation with tumor grade, pathologic stage, and clinical outcome. Urology (1999) 1.11
Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol (1997) 1.11
Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer (1999) 1.09
Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol (1993) 1.08
Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. Int J Radiat Oncol Biol Phys (1997) 1.08
Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol (2000) 1.07
Impact of patient age on biochemical recurrence rates following radical prostatectomy. J Urol (2007) 1.06
Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol (1990) 1.03
Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy? J Urol (1999) 1.03
Impact of radical prostatectomy in the management of clinically localized disease. J Urol (1994) 1.03
The prognostic impact of seminal vesicle involvement found at prostatectomy and the effects of adjuvant radiation: data from Southwest Oncology Group 8794. J Urol (2008) 1.02
Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology (1998) 1.01
Salvage or adjuvant radiation therapy: counseling patients on the benefits. J Natl Compr Canc Netw (2010) 0.97
Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implications for staging systems and predictive models. J Clin Oncol (2001) 0.96
Tumor angiogenesis is associated with progression after radical prostatectomy in pT2/pT3 prostate cancer. Prostate (2000) 0.95
Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma. Urology (1999) 0.95
Disease recurrence and progression in untreated pathologic stage T3 prostate cancer: selecting the patient for adjuvant therapy. J Urol (1997) 0.94
Impact of patient age at treatment on outcome following radical retropubic prostatectomy for prostate cancer. J Urol (2006) 0.94
Should Gleason score 7 prostate cancer be considered a unique grade category? Urology (1999) 0.93
Should we replace the Gleason score with the amount of high-grade prostate cancer? Eur Urol (2006) 0.93
Prognostic indicators in patients with seminal vesicle involvement following radical prostatectomy for clinically localized prostate cancer. J Urol (1998) 0.92
Surgical control of clinically localized prostate carcinoma is equivalent in African-American and white males. Cancer (1998) 0.91
Preoperative PSA velocity and doubling time do not predict adverse pathologic features or biochemical recurrence after radical prostatectomy. Urology (2001) 0.90
Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol (1993) 0.90
Tumour control according to pathological variables in patients treated by radical prostatectomy for clinically localized carcinoma of the prostate. Br J Urol (1997) 0.89
The relationship between early biochemical failure and perineural invasion in pathological T2 prostate cancer. BJU Int (2000) 0.89
PSA outcome following radical prostatectomy for patients with localized prostate cancer stratified by prostatectomy findings and the preoperative PSA level. Urol Oncol (2005) 0.88
"PSA-itis": knowledge of serum prostate specific antigen and other causes of anxiety in men with metaststic prostate cancer. J Urol (2002) 0.88
Prognostic significance of capsular invasion and capsular penetration in patients with clinically localized prostate cancer undergoing radical prostatectomy. Prostate (1995) 0.88
Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab (2002) 1.40
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study. Clin Cancer Res (2006) 0.97
Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy. Urology (2006) 0.91
Alvimopan for prevention of postoperative paralytic ileus in radical cystectomy patients: a cost-effectiveness analysis. BJU Int (2012) 0.85
The modulation of prostate cancer risk with alpha-tocopherol: a pilot randomized, controlled clinical trial. J Urol (2005) 0.79
High-grade prostate cancer: favorable results in the modern era regardless of initial treatment. ISRN Oncol (2012) 0.77
Prostate cancer detection strategies. Curr Urol Rep (2006) 0.76
Evaluation of mechanical bowel preparation methods in urinary diversion surgery. Can J Urol (2006) 0.75
What's new in the field of prostate cancer chemoprevention? Curr Urol Rep (2005) 0.75
Efficacy of taxotere in the post-prostatectomy setting. Curr Urol Rep (2006) 0.75
What's new in the field of prostate cancer chemoprevention? Curr Oncol Rep (2004) 0.75
Local and systemic therapy for patients with metastatic prostate cancer: should the primary tumor be treated? Curr Urol Rep (2005) 0.75
Dealing with non-cancerous findings on prostate biopsy. Curr Urol Rep (2006) 0.75
Intraductal carcinoma of the prostate in the ejaculatory duct. Int J Surg Pathol (2010) 0.75
The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions. Urol Clin North Am (2004) 0.75
First International Conference on Chemoprevention of Prostate Cancer. Overview consensus statement. J Urol (2004) 0.75